Healthcare / BiotechnologyHKSE
$0.72
+0.02 (+2.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $18.6M · quality 74.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
24.0x
↑EV/EBITDA
28.7x
↑ROE
2.0%
↑Gross Margin
27.0%
↓Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.8%
FCF CAGR
+30.8%
FCF margin
12.6%
FCF / Net income
4.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $256.7M · net income $6.8M · FCF $32.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $256.7M | $256.7M | $254.9M | $259.9M | $250.4M |
| Net Income | $6.8M | $6.8M | $791000.00 | $10.8M | $25.7M |
| EBITDA | $54.0M | $54.0M | $50.0M | $57.2M | $69.9M |
| EPS | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Gross Margin | 27.0% | 27.0% | 27.4% | 30.2% | 35.6% |
| Operating Margin | 7.6% | 7.6% | 3.7% | 7.9% | 14.1% |
| Net Margin | 2.6% | 2.6% | 0.3% | 4.2% | 10.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.46 | 0.42 | 0.35 |
| Current Ratio | 1.33 | 1.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $32.3M | $32.3M | $14.8M | $18.6M | $14.4M |
| Returns | |||||
| ROE | 2.0% | 2.0% | 0.2% | 3.2% | 7.7% |
| Valuation | |||||
| P/E | 24.00 | 24.00 | 3950.00 | 415.38 | 241.46 |
| EV/EBITDA | 28.71 | 28.71 | 66.42 | 79.73 | 88.99 |
| P/B | 4.21 | 4.21 | 9.64 | 13.05 | 18.59 |
| Growth & Yield | |||||
| Revenue Growth | 0.7% | 0.7% | -1.9% | 3.8% | — |
| EPS Growth | 725.0% | 725.0% | -92.3% | -57.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
168.5%
EPS terminal req.
$0.06
Spread vs growth
556.5%
5Y implied EPS CAGR
87.9%
EPS terminal req.
$0.08
Spread vs growth
637.1%
10Y implied EPS CAGR
43.8%
EPS terminal req.
$0.12
Spread vs growth
681.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.9%
Start / end P/E
2900.0x → 218.2x
EPS bridge
0.00 → 0.00
Residual
-670.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.